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Abstract
Introduction: Fluconazole is a widely used antifungal agent with a possible side effect of fixed drug
eruption. However, this adverse drug effect is absent from the reported list of possible side effects of
fluconazole. We are presenting a rare case in our report.
Case presentation: A 25-year-old Iranian woman developed fixed drug eruptions on different sites
of her body after taking five doses of fluconazole to treat vaginal candidiasis. A positive patch test,
positive oral challenge test and skin biopsy were all found to be consistent with fixed drug eruption.
Conclusion: Fluconazole is a widely prescribed drug, used mainly to treat candidiasis. Fixed drug
eruption as a possible side effect of Fluconazole is not well known and thus, the lesions may be
misdiagnosed and mistreated. Based on our findings, which are consistent with a number of other
practitioners, we recommend adding fixed drug eruption to the list of possible side effects of
fluconazole.
Introduction
Fluconazole (Diflucan®) is a broadly used bis-triazole
antifungal agent. It functions mainly by inhibiting
cytochrome P45014a-demethylase (P45014DM), which
in turn, prevents the conversion of lanosterol to ergosterol
in the sterol biosynthesis pathway. Fluconazole seems to
have a superior selectivity for fungus compared to human
P-450-enzymes [1]. It is used to treat vaginal, orophar-
yngeal, and esophageal candidiasis; additionally, it is used
to treat cryptococcal meningitis and prevent fungal
infections in immunocompromised patients. In some
literature, fluconazole has proven to be effective for
treatment of Candida urinary tract infections, peritonitis,
and systemic Candida infections including candidemia,
disseminated candidiasis, and pneumonia [2]. The body
clears fluconazole primarily by renal excretion. Accord-
ingly, the dosage should be reduced in proportion to any
reduction inkidney function. In general, thebody tolerates
fluconazole quite well. Still, there are commonly observed
adverse events such as nausea, vomiting and elevations in
liver function tests. Less common side effects are head-
aches, dizziness, diarrhea, stomach pain, heartburn,
change in ability to taste food, an upset stomach, extreme
fatigue, appetite loss, pain in the right upper quadrant,
jaundice, dark urine, pale stools, flu-like symptoms and
seizures. Observed hypersensitivity reactions are anaphy-
lactic reactions, angioedema and facial edema, pruritus,
urticaria, erythematous or maculopapular rash and
Page 1 of 4
(page number not for citation purposes)exfoliative skin reactions, including Stevens Johnson
Syndrome (SJS) and toxic epidermal necrolysis [3].
Fixed drug eruption (FDE) is characterized by single or
multiple skin lesions that occur at the same siteeach time a
drug is administered. However, the number and size of
sites may increase after each exposure. Lesions are usually
round or oval and well defined. Swelling and redness of
skin are typically seen within 30 minutes to eight hours
after exposure. Lesions are more commonly seen in the
extremities, genital areas and perianal areas, and may also
appear in other locations such as the mucosal area.
Persistent hyperpigmentation on the site of the lesion is
normally seen after healing. Accompanying systemic
symptoms are mild in FDE. The drugs mostly reported
to cause FDE are: cotrimoxazole, tetracycline, metamizole,
phenylbutazone, paracetamol, acetylsalicylic acid,
NSAIDS, metronidazole, tinidazole, chlormezanone,
amoxicillin, ampicillin, erythromycin, belladonna,
griseofulvin, phenobarbitone, diflunisal, pyrantel pamo-
ate, clindamycin, allopurinol, orphenadrine, albendazole,
dapsone, phenolphthalein, oral contraceptives, phenace-
tin, doxycycline, minocycline, panmycin, sulfonamide,
Figure 1. Fixed drug eruption induced by fluconazole,
upper lip area.
Figure 2. Symmetrical fixed drug eruption on legs due to
fluconazole.
Figure 3. Fixed drug eruption due to fluconazole (right
popliteal area).
Figure 4. Histopathology of skin biopsy (left popliteal area).
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hyoscine butylbromide, and quinine [3,4].
Case presentation
A 25-year-old woman received five doses of fluconazole
(150 mg) once a month for recurrent vaginal candidiasis.
She was healthy but had a family history of atopic
dermatitis. She noticed a red erythematous macule on the
medial side of her right popliteal fossa after taking her
second dose of fluconazole. With time, the macule faded,
but a violet pigmentation developed. A month later, after
takinganotherdose,sheagaindevelopedtwomacules;one
developed on exactly the same site and the other in the left
popliteal fossa. Both patches were symmetrical and similar
in appearance. Again, the patches faded and hyperpigmen-
ted areas developed. At this point, she was examined by a
dermatologist and misdiagnosed with lichen planus and
treated with topical clobetasol that led to the development
ofstriaeonbothsites.Fourhoursaftertakingthefifthdose,
the macules reappeared along with a new macule on her
right upper lip. She suspected that the symptoms were
causedbyfluconazoleandagainvisitedadermatologist.An
oral challenge test with fluconazole (150 mg) was
conducted 4 weeks later and showed similar signs three
hours after intake. Local provocation was performed with
10% fluconazole in petrolatum on the left pigmented area
and 10% fluconazole in ethanol on the right pigmented
area. For comparison, the same compounds were tested on
normal skin on the back. After 16 hours, two red patches
developedonbothsidesofherlegsandnoneonherback.A
skin biopsy specimen from the left popliteal area revealed
a lichenoid infiltrate, a basal cell vacuolization, dermal
melanophages and a superficial perivascular lymphocytic
infiltrate consistent with FDE. Despite having a family
history of atopic dermatitis, she had no major or minor
symptoms of atopic dermatitis and she denied having any
other reaction to drugs or any allergy history. We
recommended that she discontinue using fluconazole.
To determine the cause of the recurrent vaginitis, her
complete medical history was taken. She had experienced
mid cycle spotting while using low-dose oral contra-
ceptives therefore she switched to using high-dose oral
contraceptives 2 years before our study. She was also
working in a fitness center during that time and she
mentioned that she wore a wet swimsuit for long periods
of time and used tight synthetic clothes all of which were
risk factors for vaginal candidiasis [16]. At this time, we
recommended that she use other contraceptive methods
for example, condoms. Furthermore, we asked her to
wear cotton underwear and informed her of preventive
methods of candidiasis. We followed up with her after
6 months and she mentioned she had not experienced
any other episode of candidiasis since then.
Discussion
We discuss a rare case of fixed drug eruption due to
fluconazole. We have found 16other reports of FDEdue to
fluconazole although the site and appearance of the skin
lesions were different among the reported cases. Thirteen
out of 17 cases of FDE due to fluconazole, including ours,
occurred in women [6,8-10,12-14]. Most previous studies
on FDE due to drugs demonstrated a higher occurrence in
men compared to women according to research by
Mahboob and colleagues [4]. Contrarily, in their study,
the ratio of women to men was 1.1:1 [4]. The number of
reported cases of FDE due to fluconazole is too low to be
discussed epidemiologically. However, the higher ratio of
women could be due to the higher prescription of
fluconazole to women due to vaginal candidiasis. The
youngest patient reported was 19-years-old [11] while the
oldest one was 66-years-old [7]. The mean age ± SD of
men who experienced FDE due to drugs in previous
studies was 30.4 ± 17 while it was 31.3 ± 14 for women
[4]. In previous studies of FDE due to fluconazole, all
female patients were prescribed fluconazole for vaginal
candidiasis similar to our patient, while male patients
were prescribed fluconazole for Candida balanitis [5], oral
candidiasis [10], tinea corporis and tinea cruris [11]. In
almost all cases, eruption occurred after a couple of drug
administrations. The only common medication used by
patients was fluconazole. The most affected sites for
eruptions were limbs, palmar and plantar areas
[5,6,8,10,12] as well as the oral cavity and lips
[6,8,9,11,14,15]. A report of vulvar FDE due to flucona-
zole has also been published recently [15]. In our patient,
both popliteal fossas and the upper lip were affected.
A study by Sharma and colleagues was conducted on 125
patients who had FDE due to drugs. They reported that the
Figure 5. Histopathology of skin biopsy (left popliteal area).
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lips alone and genitalia with 20.8% and 20%, respectively.
Another study compared 450 cases of FDE and the results
showed that 48% of lesions involved the lips followed by
hands (36.8%), arms (34.6%), and legs (33.3) [4]. They
also reported that 57.6% of patients had multiple lesions
comparedto42.4%whohadasingleeruptionduetouseof
drugs [17]. In a study conducted by Mahboob et al, 16.2%
of patients with FDE had solitary lesions compared to the
remaining patients who had more than one lesion [4]. The
same study also showed that 70% of patients with FDE
experienced a bilateral involvement comparable to our
study [4]. To our knowledge, our study is the second
documentedcaseofsuccessfulpatchtestingforfluconazole
[6]. Alanko conducted a topical provocation test on 30
patientswithFDEandconcludedthatthetestisausefuland
safe method. However, a positive test is more informative
than a negative test in most drug reactions [18]. One study
demonstrated thatanoral challenge testis ausefulmethod
as a tolerance test or to exclude drug hypersensitivity in
cases of suspected drug reactions with negative skin tests
[19]. The skin test was positive in our patient. However, we
did an oral test as well that was also positive. This was
consistentwithmostofthereportedcases[5,7,8,10,11,14].
It is important to note that diagnostic tests must be done
carefully to prevent the rare occurrence of toxic epidermal
necrolysis [13]. Skin biopsies were performed in four cases
[5,6,12,14] and the histopathology was consistent with
FDE similar to our patient.
Conclusion
Fluconazole is a broadly administered medication used
mainly to treat candidiasis. FDE is one of the rare side
effects of fluconazole. However, FDE may be misdiag-
nosed and mistreated since many medical practitioners are
unaware of this uncommon side effect. Our findings are
consistent with those from a number of other practi-
tioners, thus, we recommend adding FDE to the list of
possible side effects of fluconazole.
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